Pharmacokinetics and safety of a raltegravir containing regimen in HIV-infected children aged 2 to 12 years on rifampicin for tuberculosis

Objectives:Drug–drug interactions limit current antiretroviral treatment options for HIV-infected children with tuberculosis (TB). Rifampicin (RIF) induces UDP-glucuronosyltransferase activity, accelerating the clearance of raltegravir (RAL). We sought to establish an optimal and well tolerated dose